Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-controlled randomised study

Karasawa, Katsuyuki; Sunamura, Makoto; Okamoto, Atsutake; Nemoto, Kenji; Matsuno, Seiki; Nishimura, Yasumasa; Shibamoto, Yuta

doi:10.1016/j.radonc.2008.02.007

« Previous Next »Radiotherapy & Oncology
Volume 87, Issue 3 , Pages 326-330, June 2008

Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-controlled randomised study☆

Katsuyuki Karasawa
- Department of Radiology, Tokyo Metropolitan Komagome Hospital, Japan
- Corresponding author. Katsuyuki Karasawa, Department of Radiology, Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
Makoto Sunamura
- Department of Surgery, Tohoku University School of Medicine, Japan
Atsutake Okamoto
- Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan
Kenji Nemoto
- Department of Radiology, Tohoku University School of Medicine, Japan
Seiki Matsuno
- Department of Surgery, Tohoku University School of Medicine, Japan
Yasumasa Nishimura
- Department of Radiation Oncology, Kinki University School of Medicine, Japan
Yuta Shibamoto
- Department of Radiology, Nagoya City University School of Medicine, Japan

Received 22 June 2007; received in revised form 9 February 2008; accepted 9 February 2008. published online 17 March 2008.

Abstract

Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p=0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer.